eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2010
vol. 14
 
Share:
Share:
abstract:
Review paper

Novel systemic approaches to treatment of HCC

Joanna Załuska
,
Wojciech Melerowicz
,
Ewa Prochowska
,
Piotr J. Wysocki

Współczesna Onkologia (2010) vol. 14; 1 (23–30)
Online publish date: 2010/02/25
View full text Get citation
 
PlumX metrics:
Hepatocellular cancer (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer death. HCC is highly resistant to conventional systemic therapies and prognosis for advanced HCC patients remains poor. Identification of signalling pathways responsible for HCC growth and progression such as RAS/RAF/ MEK/ERK or PI3K/AKT/mTOR has determined molecular targets whose inhibition by novel agents may improve patients’ outcome. Based on a phase III clinical trial demonstrating a significant impact on overall survival, sorafenib has been approved for treatment of advanced HCC. Many other targeted agents – monoclonal antibodies, tyrosine kinase inhibitors and serine-threonine kinase inhibitors – have been tested in phase II clinical trials and have recently entered phase III studies. The aim of this article is to review molecular mechanisms responsible for development and progression of HCC, and the role of targeted therapies in the treatment of HCC which may soon be introduced into clinical practice.
keywords:

hepatocellular cancer, tyrosine kinase inhibitors, sorafenib, chemotherapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.